Xcovery's ALK inhibitor ensartinib (X-396) Phase 2 clinical trial yields positive results
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Xcovery(http://announced that its ALK inhibitor ensartinib (X-396) had positive results in the treatment of alK-positive non-small cell lung cancer (NSCLC) patients in the phase 2 clinicaltrial(http://Detailed data from the trial have been published in the prestigious medical journal The LancetAbout Ensartinib
Ensartinib is a new type of ALK inhibitorIn in vitro tests, this inhibitor can effectively suppress a variety of almusomes of ALKEnsartinib has shown good clinical activity in Phase 1/2 clinical trials for ALK-positive NSCLCCurrently, there is a Phase 2 trial for ROS1-positive patients and a head-to-head trial of ensartinib and crizotinib ongoingXcovery has filed a regulatory application in ChinaA total of 147 patients who could be effectively assessed participated in Phase 2 clinical trials completed in ChinaThe trial was designed to assess the efficacy and safety of patients who had received crizotinib treatment but had a poor responseAccording to the Independent Review Committee (IRC), patients treated with ensartinib achieved an objective remission rate (ORR) of 52%, while 70% of patients with brain metastatic tumors reached an intracranial ORRIn this study, ensartinib also showed the activity of a range of ALK-resistant mutations, including G1202R
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
